Loading
Latest filing published 30 Dec 2016 for AEOLUS PHARMACEUTICALS, INC., €3,584.
No signal scores available.
Based on 11 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of John L. McManus in Aeolus Pharmaceuticals, Inc. In total, 17 filings cover trades dated from 30 December 2005 to 28 December 2016.
Both buying and selling appear: 14 purchases worth €33k, against 2 sales worth €5,721. Taken together, the purchases exceed the sales by €27k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 share grant.
The median purchase comes to €2,357. After 11 purchases with a full 90-day history, the hit rate stands at 9% and the median 90-day move at -27.7%. Past outcomes like these are no guarantee of what comes next.
The newest entry dates from 30 December 2016: a share grant of €3,584, in Aeolus Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 4,980 days ago, on 6 March 2013. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
16 of 16 declarations